Market News & Trends
Sandoz Proposed Biosimilar Accepted for Review by FDA
Sandoz, a Novartis Division, and the pioneer and global leader in biosimilars, announced today that the US FDA has accepted its Biologics License Application (BLA)…
Aptose Biosicences & CrystalGenomics Announce Issuance of US Patent
Aptose Biosciences Inc. recently announced that the United States Patent and Trademark Office has issued US Patent No. 9,758,508 titled 2,3-DIHYDRO-ISOINDOLE-1-ON DERIVATIVE AS BTK KINASE…
Immuno-Oncology Looks Set to Become Fifth Pillar of Cancer Treatment
Immuno-Oncology (IO) looks set to become the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and other targeted treatments according to GlobalData, a recognized…
Halozyme Lands Monster R&D Deals Worth Over $2 Billion for Drug Delivery Technology
Bristol-Myers Squibb has signed a partnership deal with San Diego-based Halozyme Therapeutics to use Halozyme’s ENHANZE drug delivery technology to develop a new way to…
DFB Pharmaceuticals Forms NanOlogy & Soria for Clinical Development of Naked Nanoparticle Platform
Demand for new cancer drugs is enormous with public and private investment skyrocketing for new technologies. Immunotherapies have captured much of the attention in recent…
APAC Drug Delivery Devices Market to Reach $5.4 Billion in 2023
Drug delivery devices market in Asia Pacific (India, China, Japan, South Korea, Australia, New Zealand, and Taiwan) region is expected to grow at CAGR 3.9%,…
Atara Biotherapeutics Receives FDA Orphan Drug Designation
Atara Biotherapeutics, Inc. recently announced that ATA230 was granted orphan drug designation for the treatment of cytomegalovirus (CMV) viremia and disease in immunocompromised patients by…
TG Therapeutics Announces Completion of Target Enrollment in Phase 3 Trial
TG Therapeutics, Inc. recently announced that target enrollment for the UNITY-CLL Phase 3 trial has been achieved. The UNITY-CLL Phase 3 trial is a randomized…
AMRI’s Global Analytical Services Introduces Comprehensive Forced Degradation Services
AMRI’s Global Analytical Services is pleased to launch a new comprehensive forced degradation service to meet the industry demand for supporting drug substance, product including…
GE Healthcare Advances the Delivery of Cell Therapies With New Thawing Technology
GE Healthcare recently introduced the first in its VIA Thaw series, the VIA Thaw CB1000 for thawing large volumes of cell therapies cryopreserved in cryo-bags.…
AELIX Therapeutics Enrolls First Patient in HIV Vaccine Trial
AELIX Therapeutics recently announced that it has enrolled the first patient in its Phase 1 clinical trial for the assessment of its proprietary HTI vaccine.…
Retrophin Announces Cooperative Research & Development Agreement
Retrophin, Inc. recently announced it has entered into a three-way Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health’s National Center for…
AMRI Expands Sterile Production Capacity
AMRI, a global contract research, development and manufacturing organization, is expanding its sterile manufacturing capacity. The addition of an aseptic pre-filled syringe filling line at…
GSK Exercises Option Over Adaptimmune’s SPEAR T-Cell Therapy Program
Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, recently announced that GlaxoSmithKline plc has exercised its option under a collaboration and license…
Novartis AG Receives First Ever FDA Approval for CAR-T
A new era in cancer treatment is now here. The US FDA recently gave the nod to Switzerland-based Novartis AG for its gene therapy cancer…
Immunovaccine Announces Achievement of Milestones in Collaboration with Zoetis
Immunovaccine Inc., a clinical-stage immuno-oncology company, recently announced the achievement of several milestones in its ongoing collaboration with global animal health company Zoetis to develop…
Genmab & Seattle Genetics to Co-Develop Tisotumab Vedotin for Solid Tumors
Genmab A/S and Seattle Genetics, Inc. recently announced that Seattle Genetics, Inc. has exercised its option to co-develop tisotumab vedotin. The companies originally entered into…
Asia-Pacific Hepatitis C Market to Surpass $8.3 Billion by 2023
The hepatitis C market across the Asia-Pacific (APAC) region, which includes India, China, Australia, South Korea and Japan, is forecast to grow from $5.3 billion…
Rexahn Pharmaceuticals Receives New US Patent
Rexahn Pharmaceuticals, Inc. recently announced that the United States Patent and Trademark Office has issued US Patent No. 9,744,167, Nanoparticulate Formulations and Compositions of Piperazine…
Abeona Therapeutics Receives FDA Breakthrough Therapy Designation
Abeona Therapeutics Inc. recently announced the US FDA has granted Breakthrough Therapy designation status to the company’s EB-101 gene therapy program for patients with Recessive…
